蛋白酪氨酸磷酸酶1B基因1484插入G变异与中国人肥胖相关

目的 确定蛋白酪氨酸磷酸酶1B（PTPIB）基因1484插入G（insG）变异是否与中国人肥胖相关。方法 选取上海地区中国人305例，用PCR／SacⅡ酶解法检测1484insG突变，突变的样本全部进行DNA序列分析。结果 正常对照组、单纯性肥胖、肥胖合并2型糖尿病组各发现8例、10例、16例PTP1B1484insG突变，正常对照组的1484insG突变率与单纯肥胖组、肥胖总组比较差异无统计学意义。但正常对照组与肥胖合并2型糖尿病组比较差异有统计学意义（P〈0．05），单纯肥胖组与肥胖合并2型糖尿病组比较差异无统计学意义（P〉0．05）。结论 PTP1B基因1484insG突变与中国人肥胖伴2型糖尿病有相关性，可能是中国肥胖人群发生2型糖尿病的遗传因素之一。     

蛋白酪氨酸磷酸酶1B基因多态性与2型糖尿病和肥胖的相关性研究

目的 研究中国人群中蛋白酪氨酸磷酸酶1B（PTP-1B）基因的单核苷酸多态性（SNP）与2型糖尿病及肥胖的相关性。方法 采用直接测序法对PTP—1B基因作SNP筛查，并在夫妻配对样本中对所检出的SNP作基因分型。结果 共检出6个SNPs位点，其中内含子区3个（15／37C→A，16／82A→G，17／301C→T），外显子区3个（E8／45C→T，E9／35G→A，E10／372G→A），其中E9／35G→A为新发现的突变类型；在病例-配偶对照研究中发现，15／37C→A，16／82A→G和17／301C→T等位基因频率在糖尿病患者和正常人配偶中差异有统计学意义（均P〈0．05），其余位点的等位基因频率在两组间的分布则无明显差异。与肥胖的相关性研究中发现15／37C→A和17／301C→T位点与男性的腰臀比（WHR）相关（P〈0．05）。结论 PTP-1B基因的SNP位点15／37C→A，16／82A→G和17／301C→T多态性可能和2型糖尿病的发病相关，其中15／37C→A和17／301C→T与男性的WHR相关。     

蛋白酪氨酸磷酸酶1B在肥胖大鼠下丘脑的表达

目的观察高脂饲料诱导的肥胖大鼠下丘脑蛋白酪氨酸磷酸酶1B（PTP-1B）的表达。方法SD大鼠20只随机分为正常饲料组和高脂饲料组喂养8周。测定大鼠Fins、BG、TG、TC、瘦素、副睾脂肪垫重量、PTP-1B活性;观察肝脏形态学改变;蛋白印迹法检测下丘脑组织中PTP-1B蛋白含量。结果（1）高脂组胰岛素敏感性降低,出现瘦素抵抗和肝脏脂肪变性;（2）高脂组大鼠下丘脑PTP-1B蛋白表达和活性增加。结论高脂饲料可诱导大鼠下丘脑PTP-1B蛋白表达和活性升高,这可能是肥胖引发下丘脑产生胰岛素抵抗和瘦素抵抗的机制之一。     

蛋白酪氨酸磷脂酶-1B基因Pro387Leu变异与2型糖尿病的相关性研究

目的　探讨广州地区汉族人中蛋白酪氨酸磷脂酶 1B(PTP 1B)基因Pro387Leu变异与2型糖尿病 (T2DM)的相关性。　方法　随机选取无亲缘关系的广州地区汉族人 5 6 7例 ,其中T2DM患者 32 9例 ,正常对照 2 38例 ,应用聚合酶链反应 限制性片段长度多态性 (PCR RFLP)进行Pro387Leu变异的检测。　结果　正常对照组PTP 1BLeu 387携带者及Leu 387等位基因频率分别是 0 8%、0 4 % ,T2DM组相应为 0 6 %、0 3% ,两组比较差异无统计学意义 (P >0 0 5 )。　结论　PTP 1B基因Pro387Leu变异与汉族人T2DM的发生不相关。     

蛋白酪氨酸磷酸酶-1B与胰岛素信号转导

蛋白酪氨酸磷酸酶-1B(PTP-1B)作用于胰岛素受体，胰岛素受体底物(IPS)1、2，生长因子受体结合蛋白(Grb)2，磷脂酰肌醇3激酶(PBK)等与胰岛素信号转导相关的蛋白，使它们的磷酸化酪氨酸残基脱磷酸，衰减胰岛素信号转导，从而产生受体后胰岛素抵抗。PTP-1B(-／-)小鼠、钒盐衍生物等PIRlB抑制剂在不同程度上能增强胰岛素敏感性，促进外周肌肉、脂肪组织对葡萄糖的摄取氧化，增加肝脏糖原合成，降低ob／oh小鼠的血糖。PIR-1B可能会成为治疗2型糖尿病与肥胖症的新靶点。     

PTP-1B基因突变的PCR-RFLP与肥胖的相关性

采用多聚酶联反应-限制性片段长度多态性方法，对110例单纯肥胖者、110例肥胖合并2型糖尿病者、120例正常对照者PTPlB基因ISV5＋3666、303位编码子进行酶切研究。结果显示PTPlB基因的P303P突变可能与肥胖发生相关，ISV5＋3666delT突变与肥胖发生不相关。     

蛋白酪氨酸磷酸酶-1B与2型糖尿病

研究证实,蛋白酪氨酸磷酸酶-1B(PTP-1B)主要通过以下几方面参与2型糖尿病的发病(1)可与胰岛素受体及其底物相作用,减弱胰岛素信号转导,引起胰岛素抵抗。(2)参与对胰岛β细胞数量的调节。(3)与瘦素抵抗及脂代谢异常关系密切,由此引发并加重2型糖尿病。目前已合成各种类型的PTP-1B抑制剂,有良好的降糖等疗效,临床应用前景广阔。     

蛋白酪氨酸磷酸酶1B的研究进展

蛋白酪氨酸磷酸酶1B（PTP1B）是2型糖尿病相关蛋白，被认为是治疗2型糖尿病一个重要的潜在靶点。因此下面对国内外有关PTP1B的研究作一综述。     

蛋白酪氨酸磷酸酶1B的研究进展

蛋白酪氨酸磷酸酶1B（PTP1B）是2型糖尿病相关蛋白，被认为是治疗2型糖尿病一个重要的潜在靶点。因此下面对国内外有关PTP1B的研究作一综述。     

高脂饮食诱导的肥胖大鼠胰腺蛋白酪氨酸磷酸酶1B表达增高

目的观察高脂饮食诱导的肥胖大鼠胰腺中蛋白酪氨酸磷酸酶1B（PTP-1B）的表达。方法选取SD大鼠20只，随机分为正常对照组10只，给予常规饲料；肥胖模型组10只，给予高脂饲料，共喂养12周。测定大鼠空腹胰岛素、血糖、甘油三酯、总胆固醇，附睾脂肪垫重量；观察肝脏形态学改变；进行葡萄糖耐量试验和胰岛素释放试验；用免疫组化和蛋白印迹法检测大鼠胰腺组织中PTP-1B蛋白的表达。用免疫沉淀法检测胰岛素受体（IR）和胰岛素受体底物1（IRS-1）磷酸化程度。结果（1）肥胖组胰岛素敏感指数显著低于对照组（0．36±0．18 vs 0．91±0．28，P〈0．05）；（2）肥胖组大鼠葡萄糖耐量受损，葡萄糖刺激的胰岛素Ⅰ相分泌反应受损；（3）肥胖组大鼠胰腺中PTP-1B蛋白与对照组相比，含量增加86％（P〈0．01）。肥胖组胰腺中胰岛素诱导的IR和IRS-1磷酸化程度都降低。结论高脂饮食诱导的肥胖大鼠胰腺中PTP-1B蛋白表达量升高，从而使胰岛素诱导的IR和IRS-1磷酸化程度降低，可能是肥胖状态下引发胰岛产生胰岛素抵抗的机制之一。     

The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population

OBJECTIVES: Diabetes mellitus type 2 (DM-2) is a complex disorder with a strong genetic background. Protein tyrosine phosphatase-1B (PTP-1B) dephosphorylates various receptor protein kinases in vitro, including the beta subunit of the insulin receptor, therefore representing a potential candidate to be involved in the polygenic pathogenesis of DM-2. Recently a Pro387Leu variant of the PTP-1B gene has been associated with an increased risk of DM-2 in a Danish population. Reports from China and Finland failed to confirm this association. DESIGN, SETTING AND SUBJECTS: The purpose of the present study was to examine the possible association between the presence of DM-2 and the Pro387Leu polymorphism in a German Caucasian population. A total of 836 subjects (age 20-92 years) participated in the study. The presence of the Pro387Leu variant of the PTP-1B gene was investigated using polymerase chain reaction (PCR) restriction fragment-length polymorphism in 402 subjects with DM-2 (231 men, 171 women, age 63.1 +/- 10.8 years, BMI 28.7 +/- 5.1 kg m(-2)) and in 434 normoglycemic age- and sex-matched control subjects (248 men, 186 women, age 64.4 +/- 6.5 years, BMI 26.5 +/- 3.7 kg m(-2)). RESULTS: Nine subjects in the control group and nine in the diabetic group (allelic frequency 0.99% in both groups) carried the Pro387Leu polymorphism. A meta-analysis on published data of >3000 subjects including our own data did not find an association between the polymorphism and DM-2. In addition, the polymorphism had no significant influence on the presence of atherosclerotic disease, whilst the influence of other known cardiovascular risk factors was confirmed. Furthermore, the impact of the mutation on metabolic and anthropometric parameters in both groups was examined. Amongst the controls there were no significant differences in BMI, HDL and LDL cholesterol or blood pressure between the two groups with or without the Pro387Leu polymorphism. The same was true for the diabetic group. Interestingly, in both diabetics and controls, Pro387Leu carriers had significantly higher triglycerides. In a logistic regression model only BMI and family history but not polymorphism were predictors of DM-2. CONCLUSIONS: In conclusion, the present data suggest that in a German Caucasian population the Pro387Leu polymorphism of the PTP-1B gene is not associated with DM-2 but may play a role in other metabolic phenotypes.     

Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities

Impaired insulin action is important in the pathophysiology of multiple metabolic abnormalities such as obesity and type 2 diabetes. Protein tyrosine phosphatase 1B (PTP1B) is considered a negative regulator of insulin signalling. This is best evidenced by studies on knockout mice showing that lack of PTP1B is associated with increased insulin sensitivity as well as resistance to obesity and in vitro studies whilst studies in animals and humans have given contradictory results. However, several studies support the notion that insulin signalling can be enhanced by the inhibition of PTP1B providing an attractive target for therapy against type 2 diabetes and obesity. In addition, recent genetic studies support the association between PTP1B with insulin resistance. The development of PTP1B inhibitors has already begun although it has become clear that is not easy to find both a selective, safe and effective PTP1B inhibitor. The objective of this paper is to review the current evidence of PTP1B in the pathophysiology of obesity, type 2 diabetes and cancer as well as in the treatment of these disorders.     

老年2型糖尿病患者PTP-1B基因多态性研究

目的 探讨蛋白酪氨酸磷酸酶-IB(protein tyrosine phosphastase-1B,PTP-1B)基因387位编码子Pro-Leu多态性与老年2型糖尿病(T2DM)的关系。方法 采用多聚酶链反应-限制性片段长度多态性(PCR-RFLP)的方法对湖北地区110例老年T2DM患者及125例正常老年对照者PTP-1B基因387位编码子酶切位点进行研究。结果 T2DM患者和正常对照者PTP-1B基因均以PP基因型为主,其频率分别为97.3％和98.4％,无显著性差异(P>0.05)。结论 未发现PTP-1B基因387位Pro-Leu多态性与老年人2型糖尿病有关。     

蛋白酪氨酸磷酸酶1B的普遍激活:胰岛素抵抗和瘦素抵抗可能的共同发病机制

近年研究发现蛋白酪氨酸磷酸酶1B(PTP1B)是胰岛素信号转导和瘦素信号转导的负性调控因子;肥胖相关胰岛素抵抗及瘦素抵抗中均存在PTP1B的过度表达。PTP1B活化可能是胰岛素抵抗和瘦素抵抗的共同机制。因此,抑制PTP1B为治疗2型糖尿病和肥胖开辟了新的途径。